Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

198 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Comparison of the responsiveness and relative effect size of the western Ontario and McMaster Universities Osteoarthritis Index and the short-form Medical Outcomes Study Survey in a randomized, clinical trial of osteoarthritis patients.
Davies GM, Watson DJ, Bellamy N. Davies GM, et al. Among authors: watson dj. Arthritis Care Res. 1999 Jun;12(3):172-9. doi: 10.1002/1529-0131(199906)12:3<172::aid-art4>3.0.co;2-y. Arthritis Care Res. 1999. PMID: 10513507 Clinical Trial.
Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis.
Ehrich EW, Davies GM, Watson DJ, Bolognese JA, Seidenberg BC, Bellamy N. Ehrich EW, et al. Among authors: watson dj. J Rheumatol. 2000 Nov;27(11):2635-41. J Rheumatol. 2000. PMID: 11093446 Clinical Trial.
Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis.
Ehrich EW, Bolognese JA, Watson DJ, Kong SX. Ehrich EW, et al. Among authors: watson dj. Am J Manag Care. 2001 Jun;7(6):609-16. Am J Manag Care. 2001. PMID: 11439734 Clinical Trial.
Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.
Watson DJ, Harper SE, Zhao PL, Bolognese JA, Simon TJ. Watson DJ, et al. MedGenMed. 2001 Nov 16;3(4):6. MedGenMed. 2001. PMID: 11965201
Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Watson DJ, et al. Arch Intern Med. 2000 Oct 23;160(19):2998-3003. doi: 10.1001/archinte.160.19.2998. Arch Intern Med. 2000. PMID: 11041909
Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis.
Pellissier JM, Straus WL, Watson DJ, Kong SX, Harper SE. Pellissier JM, et al. Among authors: watson dj. Clin Ther. 2001 Jul;23(7):1061-79. doi: 10.1016/s0149-2918(01)80092-8. Clin Ther. 2001. PMID: 11519771 Review.
Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
Watson DJ, Bolognese JA, Yu C, Krupa D, Curtis S. Watson DJ, et al. Curr Med Res Opin. 2004 Dec;20(12):1899-908. doi: 10.1185/030079904X12681. Curr Med Res Opin. 2004. PMID: 15701208
The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.
Watson DJ, Yu Q, Bolognese JA, Reicin AS, Simon TJ. Watson DJ, et al. Curr Med Res Opin. 2004 Oct;20(10):1539-48. doi: 10.1185/030079904x3078. Curr Med Res Opin. 2004. PMID: 15462687
The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis.
Ramey DR, Watson DJ, Yu C, Bolognese JA, Curtis SP, Reicin AS. Ramey DR, et al. Among authors: watson dj. Curr Med Res Opin. 2005 May;21(5):715-22. doi: 10.1185/030079905x43686. Curr Med Res Opin. 2005. PMID: 15974563
Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview.
Kamal-Bahl S, Watson DJ, Ambegaonkar BM. Kamal-Bahl S, et al. Among authors: watson dj. Clin Ther. 2009 Jan;31(1):130-40. doi: 10.1016/j.clinthera.2009.01.011. Clin Ther. 2009. PMID: 19243714
198 results
Jump to page
Feedback